Genmab A/S GMAB

GMAB Company Overview

Genmab A/S is a Denmark-based biotechnology company focused on the discovery, development, and commercialization of antibody-based therapeutics for cancer and other serious diseases. The company operates within the biotechnology and biopharmaceutical industries, with a primary emphasis on oncology, hematology, and immunology. Genmab’s business model combines proprietary antibody technology platforms, internal drug development programs, and strategic collaborations with major pharmaceutical companies. Revenue is primarily generated through product royalties, collaboration agreements, milestone payments, and licensing arrangements tied to approved and pipeline therapies.

Genmab is best known for its role in developing antibody therapeutics such as Darzalex (daratumumab), developed in partnership with Johnson & Johnson’s Janssen unit, as well as epcoritamab and other investigational oncology therapies. The company has developed proprietary technology platforms including DuoBody, HexaBody, and HexElect, which are designed to enhance antibody functionality and therapeutic effectiveness. Founded in 1999 through the merger of Medarex Europe and Genmab, the company evolved from a research-focused biotechnology enterprise into a commercially significant oncology partner with a growing proprietary pipeline and global development presence.